Printer Friendly

Browse Factor VIII topic

Articles

1-300 out of 359 article(s) nextnext page
Title Author Type Date Words
Rare Factor Deficiencies: A Retrospective, Single-center Cohort Study/Nadir Faktor Eksiklikleri: Retrospektif, Tek Merkezli Kohort Calisma. Eroglu, Nilgun; Erduran, Erol; Bahadir, Aysenur; Saruhan, Haluk Report Dec 1, 2020 3234
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People with Severe Hemophilia A and B with or Without Inhibitors. Nov 27, 2020 308
Pfizer, Sangamo dose first patient in Phase 3 study of hemophilia A treatment. Oct 7, 2020 219
Pfizer, Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment. Oct 7, 2020 629
TV REVIEWS. Oct 3, 2020 245
Sanofi announces BIVV001 Phase 1/2a study results published in NEJM. Sep 10, 2020 154
Comparative Analysis of the Occurrence and Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Hemophilic Arthropathy and Osteoarthritis. Wojdasiewicz, Piotr; Poniatowski, Lukasz A.; Kotela, Andrzej; Skoda, Marta; Pyzlak, Michal; Stangret Aug 31, 2020 8496
Roche's Spark Therapeutics Encouraged By SPK-8011 Results. Jul 13, 2020 206
Genentech says Phase IIIb STASEY study data reinforces Hemlibra safety profile. Jul 13, 2020 546
Catalyst Biosciences presents data at ISTH Virtual Congress. Jul 13, 2020 234
Genentech Says New Data from Phase IIIb Study Reinforces Safety Profile of Hemlibra in People with Hemophilia A. Jul 13, 2020 681
Spark announces updated data on SPK-8011 from Phase 1/2 trial in Hemophilia A. Jul 12, 2020 457
Takeda provides updates on Pharmacokinetic-guided Prophylaxis studies. Jul 12, 2020 541
Immunohistochemical Studies of Age-Related Changes in Cell Proliferation and Angiogenesis during the Healing of Acetic Acid-Induced Gastric Ulcers in Rats. Folorunsho Ajayi, A.; Babafemi Olaleye, S. Jun 30, 2020 6014
Sanofi announces long-term efficacy, safety data for fitusiran. Jun 19, 2020 363
Pfizer, Sangamo announce updated follow-on data from Alta study. Jun 18, 2020 205
BioMarin provides updated data from Phase 1/2 study of hemophilia A candidate. Jun 17, 2020 279
Takeda Pharmaceutical Reports Positive Hemophilia Studies Results. Jun 15, 2020 263
BioMarin provides update from Phase 1/2 study of Valoctocogene Roxaparvovec. May 31, 2020 489
AgeX Therapeutics announces collaboration with Sernova. May 29, 2020 292
uniQure presents preclinical data in SCA3, Fabry Disease, Hemophilia A. May 14, 2020 923
LFB Receives FDA Approval of Sevenfact, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors. Apr 8, 2020 714
HEMA Biologics wins FDA approval of SEVENFACT for treating adult Hemophilia A and B patients with inhibitors. Apr 7, 2020 275
HEMA Biologics wins FDA approval of SEVENFACT for treating adult Hemophilia A and B patients with inhibitors. Apr 7, 2020 279
Surgery in a Patient with Haemophilia A and Lymphoma. Cruz, M.S.; Santillan, J.; Lesser, J.; Ortiz, J.; Forzani, L.; Plaza, P. Mar 31, 2020 2290
Intracardiac Fibrinolysis and Endothelium Activation Related to Atrial Fibrillation Ablation with Different Techniques. Hajas, Orsolya; Bagoly, Zsuzsa; Toth, Noemi K.; Urbancsek, Reka; Kiss, Alexandra; Kovacs, Kitti B.; Mar 1, 2020 5636
Outrage as leading medic supports HIV doctor after infecting 1,000 people; EXCLUSIVE: Dr Christopher Ludlam said Dr Jean-Pierre Allain should keep his job -despite 1,243 people being infected with HIV through his Factor VIII blood product in the 1980s. By, Jason Evans & Alan Selby Feb 22, 2020 186
'Scottish blood products could have saved lives' NHS: English HIV deaths avoidable, say documents. JANE KIRBY Jan 3, 2020 328
Hundreds caught HIV 'over failure of England to seek help from Scotland' in manufacturing blood products. Jan 3, 2020 655
Help 'was rejected' during blood scandal. Jan 3, 2020 157
Help 'was rejected' during blood scandal. Jan 3, 2020 157
Blood tragedy 'could have been avoided'. Jan 3, 2020 124
Gene Therapy May Be Long-Term Cure for Type of Hemophilia. Dennis Thompson, HealthDay Reporter Jan 2, 2020 649
Sangamo reports transfer of SB-525 Hemophilia A Gene Therapy IND. Dec 24, 2019 191
Sangamo reports transfer of SB-525 Hemophilia A Gene Therapy IND. Dec 24, 2019 187
Sangamo Completes Early Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned USD 25m Milestone Payment. Dec 24, 2019 268
Bleeding Disorders Treatment Market Growth Insights, Sales Projection, Leading Companies, Future Trends and Application By 2023. Dec 12, 2019 1011
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition. Dec 9, 2019 964
Hemophilia Treatment Market Analysis 2019: Global Size, Recent Trends, Opportunity Assessment, Future Scope and Potential of Industry Growth By Top Leaders. Dec 3, 2019 865
Global Recombinant Plasma Protein Therapeutics Market - Industry Analysis, Size, Share, Growth, Trends & Forecast 2018-2026. Nov 25, 2019 1194
Hemophilia Treatment Market Dynamics, Pin-Point Analysis, Comprehensive Landscape, Demand Key Factors, Market Segments Regions, Therapy For Hemophilia (A, B, C) and Industry Forecast To 2023. Industry overview Nov 18, 2019 891
Bleeding Disorders Treatment Market Share Analysis, Future Growth Insights, Share Value, Leading Players and Global Industry Trends By 2023. Nov 15, 2019 1152
Intron 22 inversion real-time polymerase chain reaction detection in haemophilia A families from central South Africa. Kloppers, J.F.; Marx, G.M.; van Rensburg, W.J. Janse Nov 1, 2019 3024
Hemophilia A and B: Global Drug Forecast & Market Analysis, 2019-2028. Oct 31, 2019 1286
uniQure expects to initiate IND-enabling studies for AMT-150 in 1H20. Oct 28, 2019 197
BioMarin reports Q3 EPS 30c, consensus 6c. Financial report Oct 23, 2019 242
Chugai Pharmaceutical Co., Ltd. - Data on the use of Chugai's Hemlibra in Hemophilia A Children with or without Inhibitors were Published in Journals -- 18/10/2019. Oct 22, 2019 504
Bloody shame; Chiefs ignored infection warning. ANDY LINES Chief Reporter Oct 7, 2019 214
Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII. Nguyen, S.; Teh, P.; Zhou, J.; Chang, E.Y.; von Drygalski, A. Sep 30, 2019 2692
1,125,000 Men/Boys Expected to Have Hemophilia Worldwide; Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000. Sep 10, 2019 278
Vice-President Condemns Foreign Pharmaceutical Companies' Dumping against Iranian Rivals. Aug 12, 2019 390
Global Hemophilia Market Analysis by Type, Treatment, Therapy, and Region - Forecast to 2024. Aug 1, 2019 769
Global Blood Plasma Market (Immunoglobulin, Albumin, Factor VIII, & Alpha 1) Insights, Trends and Forecast Report 2019-2023. Report Aug 1, 2019 887
uniQure says advancing 'robust pipeline of novel gene therapy research programs'. Jul 29, 2019 364
INFECTED WITH HIV AT AGE OF 5; Family was kept in the dark about scandal of infected blood that killed thousands EXCLUSIVE. Jul 21, 2019 848
Chugai Pharmaceutical Co., Ltd. - Further Clinical Data including Long-Term Follow-up for Chugai's Hemlibra Presented at ISTH -- 9/7/2019. Jul 16, 2019 1007
Genentech Presents a Broad Range of Data for Hemlibra Demonstrating Continued Benefits for People with Hemophilia A at the ISTH 2019 Congress. Jul 12, 2019 1376
Sigilon Therapeutics Presents Data Demonstrating Feasibility of Shielded Living Therapeutics Platform for Hemophilia A at ISTH 2019 Congress. Jul 12, 2019 341
Pfizer and Sangamo reveal details of phase 1/2 Alta study of SB-525 haemophilia A gene therapy. Jul 9, 2019 203
Pfizer and Sangamo reveal details of phase 1/2 Alta study of SB-525 haemophilia A gene therapy. Jul 9, 2019 199
Takeda Release New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalised Prophylaxis with Adynovate in Severe Hemophilia A. Clinical report Jul 9, 2019 394
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) - BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe -- 8/7/2019. Jul 9, 2019 1181
Sangamo, Pfizer announce updated Phase 1/2 Alta study results for SB-525. Jul 7, 2019 304
Man kept in the dark over blood infection. Jul 5, 2019 419
Hemophilia Gene Therapy Market Scenario Focusing on Improvements Shaping Industry Growth. Jul 4, 2019 882
Hemophilia Gene Therapy Market Investigation & Industry Evolution till 2028. Jul 4, 2019 867
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) - BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019 -- 26/6/2019. Jul 4, 2019 312
Thousands of families like ours were torn apart by the NHS blood scandal. Victims were kept in the dark so they could be secretly studied. It was a form of GENOCIDE; WIDOW'S CLAIM AS SHE BELIEVES 'TRUTH WILL COME OUT' AT NEW INQUIRY. Jul 3, 2019 918
Inquiry told 'stigmatising' medical bags left outside widow's home. Jun 12, 2019 1495
BioMarin hemophilia A potential larger than anticipated, says Cantor Fitzgerald. Jun 10, 2019 102
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) - BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -- 28/5/2019. May 29, 2019 617
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) - BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A -- 28/5/2019. May 29, 2019 1541
BioMarin: valoctocogene roxaparvovec met pre-specified criteria for review. May 28, 2019 561
BioMarin: valoctocogene roxaparvovec met pre-specified criteria for review. May 28, 2019 561
BioMarin says valoctocogene roxaparvovec bleed control maintained for third year. May 28, 2019 265
'Haemophilia injections'. May 2, 2019 266
Valrox could become BioMarin's largest product, says Jefferies. May 2, 2019 149
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Apr 25, 2019 2243
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Apr 11, 2019 2243
Sangamo Therapeutics and Pfizer reveal interim data from haemophilia Phase 1/2 Alta study. Apr 4, 2019 283
Sangamo Therapeutics and Pfizer reveal interim data from haemophilia Phase 1/2 Alta study. Apr 4, 2019 279
Sangamo, Pfizer Release Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy. Apr 3, 2019 702
Sangamo, Pfizer announce Phase 1/2 interim data for SB-525 gene therapy. Apr 2, 2019 392
The European Commission approves Roche's haemophilia drug Hemlibra. Mar 15, 2019 162
The European Commission approves Roche's haemophilia drug Hemlibra. Mar 15, 2019 158
Roche announces EC approval of Hemlibra. Mar 14, 2019 145
Novo Nordisk announces approval of Biologics License Application for ESPEROCT by US FDA. Feb 20, 2019 308
Novo Nordisk announces approval of Biologics License Application for ESPEROCT by US FDA. Feb 20, 2019 304
Takeda Show Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia Aat EAHAD 2019. Clinical report Feb 7, 2019 335
Chugai's Hemlibra Gains Positive CHMP Opinion in Severe Hemophilia a Without Inhibitors. Feb 4, 2019 296
Roche says CHMP recommends EU approval of Hemlibra. Feb 1, 2019 183
Genentech's Hemlibra provided sustained bleed control in pivotal study. Dec 3, 2018 258
Bayer sees Q4 non-cash impairments and write-offs of EUR3.3B. Nov 29, 2018 162
Global Cryoprecipitated Antihemophilic Factor Market Expected to Secure Notable Revenue Share during. Nov 19, 2018 333
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse. Nov 16, 2018 162
JPMorgan downgrades Sangamo to Neutral on 'growing skepticism'. Nov 14, 2018 105
Sangamo says SMC recommends hemophilia A study continue with higher dose. Nov 9, 2018 238
Sangamo downgraded to Neutral after Hemophilia A 'about-face' at Guggenheim. Nov 9, 2018 116
Spark Therapeutics price target lowered to $48 from $60 at BMO Capital. Nov 7, 2018 110
US Food and Drug Administration approves Roche's Hemlibra. Oct 8, 2018 180
US Food and Drug Administration approves Roche's Hemlibra. Oct 8, 2018 176
Roche's Genentech announces FDA approval of Hemlibra for Hemophilia A. Oct 4, 2018 147
FAST FACTS. Oct 1, 2018 158
Shire granted EU marketing authorization for Veyvondi. Sep 12, 2018 120
USFDA approves Jivi for hemophilia A patients. Sep 4, 2018 135
USFDA approves Jivi for hemophilia A patients. Sep 4, 2018 131
Catalyst Biosciences announces publication of MarzAA Phase 1 data. Sep 4, 2018 202
Bayer passes US FDA's approval for Jivi for the routine prophylactic treatment of hemophilia A. Sep 3, 2018 331
Bayer passes US FDA's approval for Jivi for the routine prophylactic treatment of hemophilia A. Sep 3, 2018 327
FREQUENCY AND LEVELS OF FACTOR EIGHT INHIBITORS IN KNOWN HAEMOPHILIACS. Report Aug 31, 2018 2532
Bayer wins US FDA approval for Jivi for the routine prophylactic treatment of haemophilia A patients. Aug 31, 2018 299
Bayer wins US FDA approval for Jivi for the routine prophylactic treatment of haemophilia A patients. Aug 31, 2018 295
Positive Phase III Results for Genentech's Hemlibra (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine. Aug 31, 2018 139
Genentech Phase III HAVEN 3 study results published in NEJM. Aug 30, 2018 211
Emicizumab Prophylaxis Cuts Bleeding in Hemophilia A; Lower bleeding rate with administration once weekly, every two weeks versus no prophylaxis. Aug 29, 2018 300
PROFILE OF HAEMOPHILIA PATIENTS IN MANIPUR. Singh, Irom Anil; Ginzaniang, T.; Devi, P. Vedanti; Singh, A. Meina; Singh, N. Dhanachand; Yoihenba, Report Aug 13, 2018 2896
Spark Therapeutics price target lowered to $77 from $91 at Mizuho. Aug 8, 2018 121
Spark Therapeutics selloff on hemophilia A data overdone, says Barclays. Aug 8, 2018 102
Sangamo's candidate for Hemophilia A shows positive Phase 1/2 safety data. Aug 8, 2018 154
Spark says Phase 1/2 data for SPK-8011 shows a 97% reduction in ABR. Aug 7, 2018 494
Spark sinks after mean hemophilia study dose response comes in at 30%. Aug 7, 2018 129
BioMarin competitive positioning 'improved measurably,' says Piper Jaffray. Aug 7, 2018 118
Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study. Chen, Zhen-Ping; Li, Pei-Jing; Li, Gang; Tang, Ling; Zhen, Ying-Zi; Wu, Xin-Yi; Cheng, Xiao-Ling; Lu Report Aug 5, 2018 3917
Chugai Achieves Positive Results in Two Phase lll Studies of Bispecific Antibody Hemlibra. Clinical report May 25, 2018 270
Bioverativ Factor VIII Therapy Demonstrates Half-life of 37 hours with High Factor VIII Activity Following Single Low Dose. May 24, 2018 246
Roche's Hemlibra decreases bleeding in hemophilia patients in two phase three Haven studies. May 22, 2018 205
Roche's Hemlibra decreases bleeding in hemophilia patients in two phase three Haven studies. May 22, 2018 201
BioMarin hemophilia A data remain 'intriguing,' says Evercore ISI. May 22, 2018 104
Roche's Hemlibra sees positive results in Phase III HAVEN 3 study. May 21, 2018 225
Roche's Hemlibra sees positive results in Phase III HAVEN 3 study. May 21, 2018 221
BioMarin doses first patient in in a Phase 1/2 study evaluating valoctocogene. May 15, 2018 128
Genentech Garners Breakthrough Therapy Designation for Hemlibra (emicizumab-kxwh) in Hemophilia A without Factor VIII Inhibitors. Apr 19, 2018 260
US FDA grants breakthrough therapy designation to Roche's Hemlibra. Apr 19, 2018 245
US FDA grants breakthrough therapy designation to Roche's Hemlibra. Apr 19, 2018 241
Doctor urge public to be aware of Hemophilia disease. Apr 18, 2018 492
HMC: Understanding Hemophilia Symptoms Will Lead to Better Management of the Disorder. Disease/Disorder overview Apr 18, 2018 696
A Rare Seen Hemorrhage Disorder: Factor XI Deficiency Hemophilia C/Nadir Gorulen Bir Kanama Bozuklugu: Faktor XI Eksikligi Hemofili C. Ozer, Samet; Kazanci, Nafia Ozlem; Sonmezgoz, Ergun; Unuvar, Seyma; Akbulut, Nihat Apr 1, 2018 1947
EC approves Chugai's Hemlibra in people with haemophilia A with inhibitors. Feb 28, 2018 249
EC approves Chugai's Hemlibra in people with haemophilia A with inhibitors. Feb 28, 2018 245
Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in US and EU. Feb 28, 2018 152
Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in US and EU. Feb 28, 2018 153
Bioverativ publishes retrospective analysis on ELOCTATE. Feb 14, 2018 311
Haemophilia breakthrough; 2 MINUTES ON. Feb 9, 2018 193
CHMP grants Chugai's Hemlibra positive opinion in haemophilia A with inhibitors. Jan 29, 2018 223
CHMP grants Chugai's Hemlibra positive opinion in haemophilia A with inhibitors. Jan 29, 2018 219
Shire receives marketing authorisation from the European Commission for Adynovi. Jan 18, 2018 197
Shire receives marketing authorisation from the European Commission for Adynovi. Jan 18, 2018 193
Shire granted Marketing Authorization for Adynovi in Europe. Jan 15, 2018 119
Sanofi Acquires Bioverativ for $11,6B. Jan 1, 2018 351
Successful Outcome of Severe Intra-cerebral Bleeding Associated with Acquired Factor V Inhibition: Utilization of Multiple Therapeutic Agents. Andreadis, Panagiotis; Kafantari, Katerina; Agapidou, Aleka; Vakalopoulou, Sofia; Vlachaki, Efthymia Clinical report Jan 1, 2018 1924
Spindle Cell Hemangioma in the Mucosa of the Upper Lip: A Case Report and Review of the Literature. Murakami, Kazuhiro; Yamamoto, Kazuhiko; Sugiura, Tsutomu; Kirita, Tadaaki Jan 1, 2018 3499
A Case of a Patient Who Is Diagnosed with Mild Acquired Hemophilia A after Tooth Extraction Died of Acute Subdural Hematoma due to Head Injury. Kitamura, Tomohisa; Sato, Tsuyoshi; Ikami, Eiji; Fukushima, Yosuke; Yoda, Tetsuya Jan 1, 2018 1276
Hemophilia A Complicated by Ulcerative Colitis. Olivier, Maxim; Madruga, Mario; Carlan, S.J.; Ge, Li Jan 1, 2018 1222
Acquired Factor VIII Inhibitor Presenting as Occult GI Bleeding. Cano, Carlos I. Pacheco; Arosemena, Marilyn A.; Iordanov, Roumen B.; Lingamaneni, Ankitha; Aneja, An Jan 1, 2018 1833
Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review. Murray, Nigel P.; Munoz, Lorena; Minzer, Simona; Lopez, Marco Antonio Jan 1, 2018 2624
Management of Acquired Hemophilia A in Elderly Patients. Yamaguchi, Tomoya; Kudo, Naoko; Endo, Susumu; Usui, Takeo; Imashuku, Shinsaku Jan 1, 2018 3831
Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma. Maas, Dominique; Gorkom, Britta Laros-van; Gianotten, Sarnie; Cruijsen, Marjan; van Heerde, Waander; Jan 1, 2018 2055
CALIDAD DE VIDA: UN ASPECTO OLVIDADO EN EL PACIENTE CON HEMOFILIA. Villegas Alzate, Juan Diego; Martinez Sanchez, Lina Maria; Jaramillo Jaramillo, Laura Isabel Jan 1, 2018 4870
Genentech Study Shows Monthly Dosing with Hemlibra (emicizumab-kxwh) Controls Bleeds in Hemophilia A. Dec 11, 2017 266
Positive interim results in Phase III study for Chugai's emicizumab. Dec 7, 2017 287
Positive interim results in Phase III study for Chugai's emicizumab. Dec 7, 2017 283
Genentech Study of Hemlibra (emicizumab-kxwh) Shows Significant Reduction of Bleeds in Hemophilia A. Nov 27, 2017 354
The United States Food and Drug Administration approves Roche's Hemlibra. Nov 20, 2017 215
The United States Food and Drug Administration approves Roche's Hemlibra. Nov 20, 2017 211
FDA approves Chugai Pharmaceutical's bispecific antibody emicizumab. Nov 17, 2017 240
FDA approves Chugai Pharmaceutical's bispecific antibody emicizumab. Nov 17, 2017 236
ANTROPOMETRIA E FORCA MUSCULAR DE INDIVIDUOS HEMOFILICOS DA CIDADE DE JOAO PESSOA-PB/Antropometry and muscular force of hemophilic individuals of the city of Joao Pessoa-PB. Targino, Moises Arcanjo, Jr.; de Araujo Leite Filho, Marcos Antonio; Montenegro, Ramon Cunha; Barbos Nov 1, 2017 2773
FDA Grants Breakthrough Therapy Designation for BioMarin's Investigational Gene Therapy for Hemophilia A. Oct 27, 2017 464
CLINICAL PROFILE OF HAEMOPHILIA IN CHILDREN IN A TERTIARY CARE CENTRE. Varghese, Sajini; Padmakumar, Naranathu Narayanannair Report Oct 12, 2017 2061
Sangamo, Pfizer Treat First Patient in Clinical Trial Evaluating Investigational Gene Therapy for Hemophilia A. Aug 28, 2017 312
US FDA grants priority review to Roche's emicizumab prophylaxis (preventative). Aug 25, 2017 193
US FDA grants priority review to Roche's emicizumab prophylaxis (preventative). Aug 25, 2017 189
Genentech Receives Priority Review for Emicizumab for Hemophilia A with Inhibitors. Aug 25, 2017 292
Shire enters licence agreement for Novimmune bi-specific antibody. Jul 19, 2017 233
Shire enters licence agreement for Novimmune bi-specific antibody. Jul 19, 2017 229
Shire files investigational new drug application for SHP654 with US FDA. Jul 10, 2017 203
Shire files investigational new drug application for SHP654 with US FDA. Jul 10, 2017 199
Genentech Studies Show Positive Results for Emicizumab in Hemophilia A With Inhibitors. Jun 27, 2017 176
FDA Accepts Bioverativ Investigational New Drug Application for BIVV001 to Treat Hemophilia A. Jun 13, 2017 287
Sobi's Elocta wins approval in Saudi Arabia for Haemophilia A treatment. May 18, 2017 231
Sobi's Elocta wins approval in Saudi Arabia for Haemophilia A treatment. May 18, 2017 227
Global Factor VIII Deficiency Treatment Market to Grow at a CAGR of 5.5% by 2021, Research and Markets Forecasts. May 16, 2017 245
Hemophilia Treatment Market by Drugs, Distribution Channels, Trends and Forecast to 2021, Upcoming Research by iHealthcareAnalyst, Inc.. May 12, 2017 781
Sangamo Therapeutics, Pfizer Team on Hemophilia A Gene Therapy. May 12, 2017 465
Sangamo Therapeutics partners with Pfizer for gene therapy programmes for Hemophilia A. May 11, 2017 284
Sangamo Therapeutics partners with Pfizer for gene therapy programmes for Hemophilia A. May 11, 2017 280
Clinical profile of haemophilia patients of upper Assam--a hospital-based study. Dutta, Anupam; Dutta, Taniya Sarkar; Dey, Pranoy Report May 8, 2017 2224
Genentech reports positive results for haemophilia A drug. Financial report Apr 18, 2017 166
Genentech reports positive results for haemophilia A drug. Financial report Apr 18, 2017 162
Grifols announces donation of 140 million international blood clotting factor units to the World Federation of Hemophilia Humanitarian Aid Program. Apr 17, 2017 291
Grifols announces donation of 140 million international blood clotting factor units to the World Federation of Hemophilia Humanitarian Aid Program. Apr 17, 2017 287
TYPE 1 VON WILLEBRAND DISEASE IN ST. BERNARD DOG--CLINICAL PRESENTATION AND HEMOSTASIS PROFILE/DOENCA DE VON WILLEBRAND TIPO 1 GRAVE EM CAO DA RACA SAO BERNARDO--APRESENTACAO CLINICA E PERFIL DE HEMOSTASIA/ENFERMEDAD DE VON WILLEBRAND DE TIPO 1 EN UN PERRO DE LA RAZA DE SAN BERNARDO--PRESENTACION CLINICA Y EL PERFIL DE LA HEMOSTASIA. Dalmolin, Magnus Larruscaim; Lasta, Camila Serina; de Almeida Lacerda, Luciana; Camargo, Vanessa; Co Mar 1, 2017 2047
Octapharma and Pharmimex to invest in plant for human factor VIII products in Russia. Feb 3, 2017 204
Octapharma and Pharmimex to invest in plant for human factor VIII products in Russia. Feb 3, 2017 200
First Patients Enrolled in 24 Month Real-world Study Evaluating Swedish Orphan Biovitrum's Elocta. Jan 20, 2017 408
Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat. Rasmussen, Caroline E.; Nowak, Jette; Larsen, Julie M.; Moore, Emma; Bell, David; Liu, Kai Chiu; Sor Jan 1, 2017 7523
Pitfalls in Interventional Pain Medicine: Hyponatremia after DDAVP for a Patient with Von Willebrand Disease Undergoing an Epidural Steroid Injection. Khan, Talal W.; Yacoub, Abdulraheem Case study Jan 1, 2017 1707
Acquired von Willebrand Disease Associated with Monoclonal Gammopathy of Unknown Significance. Basnet, Sijan; Lin, Catherine; Dhital, Rashmi; Mir, Izza; Mohanty, Elan; Tharu, Biswaraj; Ghimire, S Clinical report Jan 1, 2017 2038
Successful Management of Acquired Hemophilia A Associated with Bullous Pemphigoid: A Case Report and Review of the Literature. Binet, Quentin; Lambert, Catherine; Sacre, Laurine; Eeckhoudt, Stephane; Hermans, Cedric Clinical report Jan 1, 2017 3461
Quercetin Inhibits Pulmonary Arterial Endothelial Cell Transdifferentiation Possibly by Akt and Erk1/2 Pathways. Huang, Shian; Zhu, Xiulong; Huang, Wenjun; He, Yuan; Pang, Lingpin; Lan, Xiaozhong; Shui, Xiaorong; Jan 1, 2017 4664
Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. Fei, Xianming; Wang, Huan; Yuan, Wufeng; Wo, Mingyi; Jiang, Lei Report Jan 1, 2017 4966
Shire plc wins US FDA's approval for ADYNOVATE for twice-weekly dosing schedule for the treatment of hemophilia A in pediatric patients. Dec 28, 2016 322
Shire plc wins US FDA's approval for ADYNOVATE for twice-weekly dosing schedule for the treatment of hemophilia A in pediatric patients. Dec 28, 2016 318
USFDA approves Shire's ADYNOVATE. Dec 28, 2016 168
USFDA approves Shire's ADYNOVATE. Dec 28, 2016 164
Deteccion de mutaciones en el gen F8 en mujeres portadoras y en pacientes con hemofilia A. Identificacion de una mutacion nueva. Lopez-Vasquez, Lucia; Albanez, Silvia; Pestana, Carolina; Porco, Antonietta Dec 1, 2016 4201
Swedish Orphan Biovitrum announces approval for Elocta in Kuwait for the treatment of Haemophilia A. Nov 22, 2016 272
Swedish Orphan Biovitrum announces approval for Elocta in Kuwait for the treatment of Haemophilia A. Nov 22, 2016 268
HEMOPHILIA CARE IN PAKISTAN. Oct 31, 2016 564
Swedish Orphan Biovitrum's Elocta receives national reimbursement in Spain. Sep 26, 2016 259
Swedish Orphan Biovitrum's Elocta receives national reimbursement in Spain. Sep 26, 2016 255
Sobi's Elocta product approved for reimbursement in UK, Italy and France. Sep 22, 2016 214
Sobi's Elocta product approved for reimbursement in UK, Italy and France. Sep 22, 2016 218
Biogen to Spin-Off Hemophilia-Focused Company Called Bioverativ. Aug 11, 2016 347
Market Report, "Bleeding Disorders Treatment Market - Global Forecast to 2021", published. Jul 20, 2016 516
Swissmedic approves Biovitrum AB's Elocta. Jun 29, 2016 156
Swissmedic approves Biovitrum AB's Elocta. Jun 29, 2016 152
Now Available: Hemophilia A - Pipeline Review, H1 2016. Jun 29, 2016 490
Sobi's Elocta receives approval in Switzerland for treatment of Haemophilia A. Jun 28, 2016 249
Sobi's Elocta receives approval in Switzerland for treatment of Haemophilia A. Jun 28, 2016 245
Biogen to spin off hemophilia business. Jun 1, 2016 583
EC APPROVES TRANSFER OF MARKETING AUTHORIZATION. Mar 31, 2016 680
BioMarin Pharmaceutical wins EC's orphan drug designation for BMN 270 for treating hemophilia A. Mar 25, 2016 260
BioMarin Pharmaceutical wins EC's orphan drug designation for BMN 270 for treating hemophilia A. Mar 25, 2016 256
Bayer's Kovaltry haemophilia A drug receives US FDA approval. Mar 21, 2016 187
Bayer's Kovaltry haemophilia A drug receives US FDA approval. Mar 21, 2016 183
Bayer receives US FDA approval for KOVALTRY haemophilia trreatment. Mar 18, 2016 142
Bayer receives US FDA approval for KOVALTRY haemophilia trreatment. Mar 18, 2016 138
BioMarin's gene therapy treatment BMN 270 awarded US FDA's orphan drug designation for Hemophilia A. Mar 2, 2016 336
BioMarin's gene therapy treatment BMN 270 awarded US FDA's orphan drug designation for Hemophilia A. Mar 2, 2016 332
Baxalta submits sBLAs to the US FDA for ADYNOVATE for treating children with hemophilia A. Feb 26, 2016 313
Baxalta submits sBLAs to the US FDA for ADYNOVATE for treating children with hemophilia A. Feb 26, 2016 309
SOBI AND BIOGEN'S ELOCTA APPROVED IN EUROPE. Jan 1, 2016 736
Implantable cell-based device could offer treatment for hemophilia. Jan 1, 2016 270
Ninos con hemofilia y su atencion odontologica por estomatologia pediatrica. Revision de la literatura. Grandas Ramirez, Angela Liliana Jan 1, 2016 7205
Hemophilia Treatment ACE910 Bypasses Factor VIII Inhibitor in Affinity Biologicals Plasmas. Dec 11, 2015 353
Baxalta Incorporated unveils ADYNOVATE twice-weekly dosing schedule for treating hemophilia A. Dec 1, 2015 220
Baxalta Incorporated unveils ADYNOVATE twice-weekly dosing schedule for treating hemophilia A. Dec 1, 2015 216
Market Report, "Global Hemophilia A Market 2015-2019 - Industry Analysis", published. Nov 13, 2015 419
EpiCast Report: Hemophilia - Epidemiology Forecast to 2024 - New Market Research Report. Nov 9, 2015 531
Acquired hemophilia A: a rare cause of gross hematuria. Hosier, Gregory W.; Mason, Ross J.; Robinson, K. Sue; Bailly, Gregory G. Report Nov 1, 2015 1732
Baxalta passes Health Canada's approval for OBIZUR for Acquired Hemophilia A. Oct 16, 2015 263
Baxalta passes Health Canada's approval for OBIZUR for Acquired Hemophilia A. Oct 16, 2015 259
Intracranial hemorrhage in a child of hemophilia: a case report. Chaudhari, Pankaj; Chitnis, Ashutosh; Pawar, Saurabh; Gursale, Akshay; Pranay, Ishan Oct 1, 2015 1085
BioMarin Pharmaceutical treats first patient under Phase 1/2 trial with BMN 270 for hemophilia A. Sep 29, 2015 342
BioMarin Pharmaceutical treats first patient under Phase 1/2 trial with BMN 270 for hemophilia A. Sep 29, 2015 338
FDA clears hemophilia I.V. medication for market. Sep 28, 2015 386
Genentech receives breakthrough therapy designation for ACE910. Sep 8, 2015 133
Genentech receives breakthrough therapy designation for ACE910. Sep 8, 2015 129
Now Available: Hemophilia A - Pipeline Review, H1 2015. Aug 12, 2015 434
Commentary. Favaloro, Emmanuel J. Report Jul 1, 2015 463
Commentary. Nichols, William L. Report Jul 1, 2015 402
Diagnostic evaluation of our patients with hemophilia A: 17-year experience. Karaman, Kamuran; Akbayram, Sinan; Garipardic, Mesut; Oner, Ahmet Fayik Report Jun 1, 2015 4688
ELOCTA EARNS ORPHAN DRUG DESIGNATION IN SWITZERLAND. Jun 1, 2015 379
Affinity Biologicals Inc. Introduces Laboratories to the New Factor VII Kit to Their Line of Factor VIII Inhibitor Kits. May 8, 2015 276
WIPED OUT. Mar 24, 2015 1218
OPKO submits investigational NDA to begin Phase 2a Trial for Factor VIIa-CTP for treating hemophilia. Feb 2, 2015 245
OPKO submits investigational NDA to begin Phase 2a Trial for Factor VIIa-CTP for treating hemophilia. Feb 2, 2015 241
Calidad de vida y hemofilia: Una revision de la literatura. Munoz Grass, Luis Fernando; Palacios-Espinosa, Ximena Jan 1, 2015 10800
Apitope receives orphan medicinal product designation for ATX-F8-117. Nov 27, 2014 201
Apitope receives orphan medicinal product designation for ATX-F8-117. Nov 27, 2014 197
European Medicines Agency validates marketing authorisation application for Elocta. Nov 4, 2014 239
European Medicines Agency validates marketing authorisation application for Elocta. Nov 4, 2014 235
The US Food and Drug Administration approves Baxter International's Obizur. Oct 28, 2014 150
The US Food and Drug Administration approves Baxter International's Obizur. Oct 28, 2014 154
Baxter International wins US FDA authorisation for OBIZUR for treating bleeding episodes in adults with acquired hemophilia A. Oct 27, 2014 272
Baxter International wins US FDA authorisation for OBIZUR for treating bleeding episodes in adults with acquired hemophilia A. Oct 27, 2014 268
Baxter International achieved positive results from its Phase III trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm. Oct 1, 2014 255
Affinity Biologicals launches Factor VIII, Factor IX Deficient plasma products in Canada, Europe. Sep 1, 2014 177
Baxter opens Singapore biologies facility. Sep 1, 2014 207
Affinity Biologicals Presents New Health Canada & CE Marked Plasmas for Diagnostic Use and Hemostasis Research in Canada & Europe. Aug 29, 2014 314
Affinity Biologicals Introduce Upgraded Collection of VisuLize[TM] Antigen ELISA Kits. Aug 21, 2014 355
Global Blood Plasma Market Report: 2014 Edition - New Report by Koncept Analytics. Jul 7, 2014 896
Affinity Biologicals Now Offers a Variety of Elisa Kits Aimed at Thrombosis Research. Jul 4, 2014 389
Affinity Biologicals unveils Visulize ELISA Kits for assessment of 4 antigens in human plasma samples. May 29, 2014 186
Bayer receives approval from US FDA for Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis in adults with hemophilia A. May 12, 2014 214
Bayer receives approval from US FDA for Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis in adults with hemophilia A. May 12, 2014 210
Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A. Apr 25, 2014 197
Baxter wins US FDA's approval for ADVATE with BAXJECT III reconstitution system for treating patients with hemophilia A. Apr 25, 2014 193
Biogen Idec enters into license agreement with Amunix for XTENylated Factor VIII. Apr 22, 2014 176
Biogen Idec enters into license agreement with Amunix for XTENylated Factor VIII. Apr 22, 2014 172
Factor VIII-related antigen detects phenotypic change of sinusoidal to vascular endothelium in hepatic fibrosis of elderly cadavers. Mak, Ki M.; Sehgal, Priya; Harris, Cynthia K. Report Jan 1, 2014 4305
Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder. Sakurai, Yoshihiko; Takeda, Tomohiro Report Jan 1, 2014 7136
Baxter International Inc submits BLA to FDA for OBI-1 for treating patients with acquired Hemophilia A. Dec 11, 2013 259
Baxter International Inc submits BLA to FDA for OBI-1 for treating patients with acquired Hemophilia A. Dec 11, 2013 255
Baxter International Inc reports BAX 855 development programme to provide safe treatment with an extended half-life for patients with hemophilia. Nov 14, 2013 293
Baxter International Inc reports BAX 855 development programme to provide safe treatment with an extended half-life for patients with hemophilia. Nov 14, 2013 279
Recently released market study: Hemophilia A - Pipeline Review, H2 2013. Oct 16, 2013 534
Biogen Idec and Sobi partnership submits new data from Phase 3 study of ELOCTATE for Hemophilia A at XXIV ISTH Congress in Amsterdam. Jul 5, 2013 322
Biogen Idec and Sobi partnership submits new data from Phase 3 study of ELOCTATE for Hemophilia A at XXIV ISTH Congress in Amsterdam. Jul 5, 2013 308
Biogen Idec's BLA for first long-lasting Factor VIII therapy ELOCTATE for haemophilia A accepted by US FDA. May 14, 2013 274
Biogen Idec's BLA for first long-lasting Factor VIII therapy ELOCTATE for haemophilia A accepted by US FDA. May 14, 2013 270
Biogen Idec applies to the US FDA for first long-lasting factor VIII rFIXFc in Hemophilia A patients. Mar 13, 2013 251
The effectiveness of a new hemostatic agent (Ankaferd Blood Stopper) for the control of bleeding following tooth extraction in hemophilia: a controlled clinical trial / Hemofililerde Yeni Bir Hemostatik Ajanin (Ankaferd Blood Stopper) Dis Cekimi Sonrasi Kanama Kontrolune Etkisi: Kontrollu Bir Klinik Calisma. Kazancioglu, Hakki Oguz, Cakir, Onur, Ak, Gulsum, Zulfikar, Bulent Report Mar 1, 2013 4343
Acquired Factor VIII inhibitors: three cases / Edinsel Faktor VIII ihibitorleri: Uc Olgu. Kyaw, Tay Za; Jayaranee, S.; Ping, Chong Bee; Min Chin, Edmund Fui Case study Mar 1, 2013 3560
BioMarin Pharmaceutical Inc licenses Factor VIII gene therapy programme for treating Haemophilia A. Feb 22, 2013 224
BioMarin Pharmaceutical Inc licenses Factor VIII gene therapy programme for treating Haemophilia A. Feb 22, 2013 220
Common and uncommon imaging manifestations of hemophilia. Yeung, Jessie T.H.; Lee, Chiu Man; Lo, Adrian X.N.; Ma, Johnny K.F.; Fong, Julian C.Y. Report Feb 1, 2013 1127
Saudi Food and Drug Authority approves New Treatments for Hemophilia. Nov 28, 2012 616
Soft tissue bleeding in a patient with hemophilia-A/Hemofili-A'ya bagli yumusak doku kanamasi olan bir olgu. Bakan, Betul; Garipardic, Mesut; Ozkan, Fuat; Kalender, Ali Murat; Bakan, Vedat Report Sep 1, 2012 1356

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters